Evidence map›Paper›PMID 24753590›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Crystal structure of Streptococcus pyogenes EndoS, an immunomodulatory endoglycosidase specific for human IgG antibodies.

Beatriz Trastoy, Joseph V Lomino, Brian G Pierce, Lester G Carter, Sebastian Günther, John P Giddens, Greg A Snyder, Thomas M Weiss, Zhiping Weng, Lai-Xi Wang and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Group aMicrobiology spectrum · 2025
    Article
  5. Article
  6. Article
  7. Immunomodulating Enzymes fromMicroorganisms · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Potential Applications of Endo-β-Frontiers in nutrition · 2021
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Beatriz TrastoyInstitute of Human Virology and Departments of Biochemistry and Molecular Biology, Medicine, and Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201.
Joseph V Lomino
Brian G Pierce
Lester G Carter
Sebastian Günther
John P Giddens
Greg A Snyder
Thomas M Weiss
Zhiping Weng
Lai-Xi Wang
Eric J Sundberg
Institute of Human Virology · NGSLAC National Accelerator Laboratory · USUniversity of Massachusetts Amherst · USUniversity of Massachusetts Chan Medical School · US

Funding

Covergent Chemoenzymatic Synthesis of Glycopeptides and GlycoproteinsR01GM080374 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI WANG, LAI-XI · 2007 to 2021
$3.9M
Molecular basis of ADCC-mediated HIV protectionR01AI090866 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SUNDBERG, ERIC JOHN · 2010 to 2013
$2.2M
NIAID NIH HHS R01 AI090866NIAID NIH HHS R01AI090866NIGMS NIH HHS R01 GM080374
6 · The paper itself

Abstract

To evade host immune mechanisms, many bacteria secrete immunomodulatory enzymes. Streptococcus pyogenes, one of the most common human pathogens, secretes a large endoglycosidase, EndoS, which removes carbohydrates in a highly specific manner from IgG antibodies. This modification renders antibodies incapable of eliciting host effector functions through either complement or Fc γ receptors, providing the bacteria with a survival advantage. On account of this antibody-specific modifying activity, EndoS is being developed as a promising injectable therapeutic for autoimmune diseases that rely on autoantibodies. Additionally, EndoS is a key enzyme used in the chemoenzymatic synthesis of homogenously glycosylated antibodies with tailored Fc γ receptor-mediated effector functions. Despite the tremendous utility of this enzyme, the molecular basis of EndoS specificity for, and processing of, IgG antibodies has remained poorly understood. Here, we report the X-ray crystal structure of EndoS and provide a model of its encounter complex with its substrate, the IgG1 Fc domain. We show that EndoS is composed of five distinct protein domains, including glycosidase, leucine-rich repeat, hybrid Ig, carbohydrate binding module, and three-helix bundle domains, arranged in a distinctive V-shaped conformation. Our data suggest that the substrate enters the concave interior of the enzyme structure, is held in place by the carbohydrate binding module, and that concerted conformational changes in both enzyme and substrate are required for subsequent antibody deglycosylation. The EndoS structure presented here provides a framework from which novel endoglycosidases could be engineered for additional clinical and biotechnological applications.

Indexed as

Bacterial ProteinsCatalytic DomainCrystallography, X-RayGlycoside HydrolasesHumansImmunoglobulin Fc FragmentsImmunoglobulin GImmunologic FactorsModels, MolecularProtein ConformationProtein Structure, TertiaryScattering, Small AngleStreptococcus pyogenesSubstrate SpecificityX-Ray DiffractionBacterial ProteinsGlycoside HydrolasesImmunoglobulin Fc FragmentsImmunoglobulin GImmunologic FactorsNDOS protein, Streptococcus pyogenes

Identifiers

PMID24753590
PMCPMC4020096
OpenAlexW2146790448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.